Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 3Pyridoxine-dependent epilepsy 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Esophageal Neoplasms 1Carcinoma 1

Interventions

Cisplatin 24pembrolizumab 23Magnetic Resonance Spectroscopy 19Specimen Handling 16Radiotherapy, Intensity-Modulated 12Carboplatin 12Cetuximab 111,2-diaminocyclohexaneplatinum II citrate 10Platinum 9Paclitaxel 9Radiotherapy 6Radiation 6Fluorouracil 6Biopsy 5Taxes 4Nivolumab 4Docetaxel 4(225)Ac-DOTA-c(RGDyK) 4X-Rays 3Pemetrexed 3Fluorodeoxyglucose F18 3reolysin 2pralsetinib 2ipatasertib 2cemiplimab 2atezolizumab 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy, Image-Guided 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Tadalafil × Head & Neck × Clear all
NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

University of California, San Diego

Phase 2 Completed
7 enrolled 14 charts
GastrointestinalHead & Neck

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡